Related references
Note: Only part of the references are listed.Differential insulin and steroidogenic signaling in insulin resistant and non insulin resistant human luteinized granulosa cells - A study in PCOS patients
Muskaan Belani et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2018)
Effect of quercetin on biochemical parameters in letrozole-induced polycystic ovary syndrome in rats
Yanli Hong et al.
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH (2018)
Plumbagin inhibits cell proliferation and promotes apoptosis in multiple myeloma cells through inhibition of the PI3K/Akt-mTOR pathway
Hongwei Wu et al.
ONCOLOGY LETTERS (2016)
The role of thioredoxin reductase and glutathione reductase in plumbagin-induced, reactive oxygen species-mediated apoptosis in cancer cell lines
Geun Hye Hwang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Seiji Mabuchi et al.
GYNECOLOGIC ONCOLOGY (2015)
The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines
Huimin Bai et al.
ONCOTARGET (2015)
PI3K/AKT signaling pathway and cancer: an updated review
Miriam Martini et al.
ANNALS OF MEDICINE (2014)
Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Sunil Sagar et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2014)
Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells
Yan-Cong Li et al.
CANCER LETTERS (2014)
Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS)
Neoklis A. Georgopoulos et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2014)
Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome
Grace Huang et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2012)
Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries
D. Dewailly et al.
HUMAN REPRODUCTION (2011)
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis
Mark O. Goodarzi et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome
Dorte Glintborg et al.
GYNECOLOGICAL ENDOCRINOLOGY (2010)
Hairy root culture of Plumbago indica as a potential source for plumbagin
M. Gangopadhyay et al.
BIOLOGIA PLANTARUM (2008)
Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline
Ricardo Azziz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Development of polycystic ovary syndrome: involvement of genetic and environmental factors
S Franks et al.
INTERNATIONAL JOURNAL OF ANDROLOGY (2006)
Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome
R Hart et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2004)
Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome
N Brettenthaler et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
DA Altomare et al.
ONCOGENE (2004)
Insulin-lowering agents in the management of polycystic ovary syndrome
V De Leo et al.
ENDOCRINE REVIEWS (2003)
Share Paper
